Target intelligence / Profile preview

Glucose-6-phosphatase catalytic subunit 3 (G6PC3)

Target
G6PC3
Molecular classification
Enzyme, Integral membrane protein
01

Overview

Glucose-6-phosphatase catalytic subunit 3 (G6PC3) is an integral membrane enzyme localized in the endoplasmic reticulum, where it catalyzes the hydrolysis of glucose-6-phosphate to glucose and phosphate—the final reaction in gluconeogenesis and glycogenolysis. Unlike the liver-predominant G6PC isoforms, G6PC3 is expressed ubiquitously and is essential for normal glucose metabolism and neutrophil function. Mutations in the G6PC3 gene cause autosomal recessive severe congenital neutropenia, sometimes with syndromic features including cardiovascular and urogenital anomalies. There are no approved drugs that directly target G6PC3, but its mutation is diagnostic for specific congenital disorders. Loss of function can cause life-threatening metabolic and immune consequences through disruption of cellular glucose production and neutrophil viability.

Other names
Glucose-6-phosphatase 3Glucose-6-phosphatase betaG6Pase 3G6Pase-betaUbiquitous glucose-6-phosphatase catalytic subunit-related protein (UGRP)SCN4Ubiquitously expressed G6Pase catalytic subunit-related protein
02

Mechanism of action

N/A (no specific targeted therapies at present)

03

Biological functions

Glucose homeostasisHydrolysis of glucose-6-phosphate to glucose and phosphateGlycogenolysisGluconeogenesisMaintenance of neutrophil function
04

Disease associations

Severe congenital neutropenia (especially autosomal recessive forms)Dursun syndrome (severe G6PC3 deficiency)Carbohydrate metabolism disordersCardiovascular and urogenital malformations (in syndromic deficiency forms)
05

Safety considerations

Deficiency leads to broad, sometimes life-threatening clinical manifestations, such as neutropenia and multi-organ malformationsAny therapy affecting G6PC3 would carry potential risks of impairing glucose homeostasis and causing immune dysfunction
06

Interacting drugs

No approved small-molecule drugs directly target G6PC3 in clinical use at present
07

Biomarkers

Mutations in G6PC3 gene are used to diagnose severe congenital neutropenia

Beyond the preview

Go deeper on Glucose-6-phosphatase catalytic subunit 3 (G6PC3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Glucose-6-phosphatase catalytic subunit 3 (G6PC3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call